Universal Ibogaine Income Statement

Financials in millions CAD. Fiscal year is August - July.

Millions CAD. Fiscal year is Aug - Jul.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY
Period Ending	Apr '25 Apr 30, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021	Mar '21 Mar 31, 2021
Revenue	2.06	2.33	1.03	1.07	-	-
Revenue Growth (YoY)	-11.68%	126.32%	-3.81%	-	-	-
Gross Profit	2.06	2.33	1.03	1.07	-	-
Selling, General & Admin	0.62	1.04	1.61	3.66	3.8	0.06
Depreciation & Amortization Expenses	0.35	0.34	0.3	0.27	0.07	0
Research & Development	0.14	0.09	0.01	0.41	-	-
Other Operating Expenses	-0.04	-0.02	0.11	0.9	-	0.23
Total Operating Expenses	1.06	1.45	2.02	5.24	3.86	0.29
Operating Income	0.58	-0.03	-1.68	-3.08	-3.8	-0.29
Interest Income	-	-	-	-	-	0
Interest Expense	-0.15	-0.16	-0.15	-0.07	-0.02	-
Other Non-Operating Income (Expense)	-0.61	-0.99	-0.19	-5.68	0.01	-
Total Non-Operating Income (Expense)	-0.76	-1.15	-0.34	-5.75	-0	0
Pretax Income	-0.18	-1.18	-2.02	-8.83	-3.8	-0.29
Net Income	-0.18	-1.18	-2.02	-10.5	-3.87	-0.29
Net Income to Common	-0.18	-1.18	-2.02	-10.5	-3.87	-0.29
Shares Outstanding (Basic)	297	233	191	186	125	10
Shares Outstanding (Diluted)	297	233	191	186	125	10
Shares Change (YoY)	38.30%	21.54%	3.05%	48.28%	1192.18%	-91.99%
EPS (Basic)	0.01	0.01	0.01	0.06	0.03	-0.03
EPS (Diluted)	0.01	0.01	0.01	0.06	0.03	-0.03
EPS Growth	-	-	-83.33%	100.00%	-	-
Free Cash Flow	-0.66	-0.92	-1.46	-4.43	-3.25	-0.21
Free Cash Flow Per Share	-0.00	-0.00	-0.01	-0.02	-0.03	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	-
Operating Margin	28.16%	-1.10%	-162.82%	-287.56%	-	-
Profit Margin	-8.83%	-50.46%	-195.80%	-824.53%	-	-
FCF Margin	-32.20%	-39.35%	-141.50%	-413.60%	-	-
EBITDA	0.93	0.32	-1.38	-2.81	-3.73	-0.29
EBITDA Margin	45.02%	13.63%	-134.07%	-262.68%	-	-
EBIT	0.58	-0.03	-1.68	-3.08	-3.8	-0.29
EBIT Margin	28.16%	-1.10%	-162.82%	-287.56%	-	-

Updated Apr 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.